CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim
Cancer Research and Treatment. 2019;51(2):777-787.   Published online 2018 September 7    DOI: https://doi.org/10.4143/crt.2018.387

Excel Download

A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
Cancer Research and Treatment. 2019;51(2):777-787   Crossref logo
Link1 Link2 Link3

A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1
Cancer Research and Treatment. 2021;53(1):93-103   Crossref logo
Link1 Link2 Link3

71: Early experience with osimertinib as second line treatment for EGFR mutated non-small cell lung cancer (NSCLC) and detecting T790M mutations from plasma circulating tumour DNA (ctDNA)
Lung Cancer. 2017;103:S34   Crossref logo
Link1 Link2

Phase II trial of AZD9291 in second line treatment after acquired resistance with T790M mutation detected from circulating tumor DNA (LiquidLung-O-Cohort 2)
Annals of Oncology. 2017;28:v486   Crossref logo
Link1 Link2 Link3

P1.01-77 Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
Journal of Thoracic Oncology. 2018;13(10):S492   Crossref logo
Link1 Link2

Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis
Lung Cancer. 2017;110:19-25   Crossref logo
Link1 Link2

Cost-effectiveness of Osimertinib vs Docetaxel-bevacizumab in Third-line Treatment in EGFR T790M Resistance Mutation Advanced Non–Small Cell Lung Cancer in China
Clinical Therapeutics. 2020;42(11):2159-2170.e6   Crossref logo
Link1 Link2

Osimertinib-induced Stevens-Johnson syndrome in a patient with EGFR T790M mutation-positive non-small cell lung cancer
Lung Cancer. 2019;129:110-111   Crossref logo
Link1 Link2

Detection of EGFR T790M Mutation in Urinary Circulating Tumor Dna From Metastatic Non-Small Cell Lung Cancer Patients
Annals of Oncology. 2015;26:i10   Crossref logo
Link1 Link2 Link3

PUB075 Detection of T790M Mutation in Circulating Free Tumor DNA of Patients with EGFR-Positive Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology. 2017;12(11):S2390   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.